GLP-1 and Cardiovascular Health

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

GLP-1 receptor agonists, originally for diabetes, also reduce cardiovascular risk by improving endothelial function, lowering inflammation, blood pressure, and weight. Clinical trials show they cut major heart events in high-risk patients.

# GLP-1 and Cardiovascular Health

Glucagon-like peptide-1 (GLP-1) has emerged as a significant player not only in metabolic health but also in cardiovascular disease management. Originally studied for its role in glucose regulation and diabetes treatment, GLP-1 and its receptor agonists have demonstrated promising benefits for heart health. This article explores the relationship between GLP-1 and cardiovascular health, the mechanisms involved, clinical evidence supporting its use, and practical considerations for incorporating GLP-1 therapies.

---

What is GLP-1?

GLP-1 is an incretin hormone secreted by the intestinal L-cells in response to food intake. It enhances insulin secretion from the pancreas in a glucose-dependent manner, inhibits glucagon release, slows gastric emptying, and promotes satiety. These effects make GLP-1 a key regulator in blood sugar control and appetite.

Because native GLP-1 is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), synthetic GLP-1 receptor agonists (GLP-1 RAs) have been developed to provide longer-lasting effects. These agents are widely used to treat type 2 diabetes mellitus (T2DM).

---

GLP-1 and Cardiovascular Health: The Connection

Cardiovascular Disease and Diabetes

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide, especially among individuals with T2DM. Patients with diabetes have a two- to four-fold increased risk of heart disease, stroke, and related complications.

Traditional glucose-lowering therapies have sometimes failed to reduce cardiovascular risk, prompting the investigation of newer agents like GLP-1 RAs for potential heart-protective effects beyond glycemic control.

Mechanisms of Cardiovascular Protection by GLP-1

Research indicates several mechanisms by which GLP-1 and its receptor agonists contribute to cardiovascular health:

  • Improved Endothelial Function: GLP-1 enhances nitric oxide production, promoting vasodilation and improved blood flow.
  • Anti-Inflammatory Effects: GLP-1 reduces systemic inflammation, a key driver of atherosclerosis.
  • Reduction in Blood Pressure: GLP-1 RAs have mild antihypertensive effects.
  • Weight Loss: GLP-1 RAs promote satiety and reduce body weight, which lowers cardiovascular risk.
  • Improved Lipid Profile: Some evidence suggests beneficial effects on cholesterol and triglyceride levels.
  • Direct Cardiac Effects: GLP-1 receptors in the heart may improve myocardial function and reduce ischemic injury.

    • ---

    Clinical Evidence Supporting GLP-1 for Cardiovascular Health

    Several large-scale cardiovascular outcomes trials (CVOTs) have evaluated GLP-1 receptor agonists in patients with T2DM and established cardiovascular disease or high risk.

    Key Trials

  • LEADER Trial (Liraglutide): Demonstrated a 13% reduction in major adverse cardiovascular events (MACE) including cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
  • SUSTAIN-6 Trial (Semaglutide): Showed a 26% reduction in MACE with semaglutide.
  • REWIND Trial (Dulaglutide): Reported a 12% reduction in cardiovascular events, even in patients with lower baseline cardiovascular risk.
  • AMPLITUDE-O Trial (Efpeglenatide): Found significant cardiovascular benefits including reduced hospitalization for heart failure.

    • These trials collectively support that GLP-1 receptor agonists can reduce cardiovascular events, improve survival, and provide benefits independent of glucose lowering.

    ---

    Practical Protocols and Dosing Information

    GLP-1 Receptor Agonists Commonly Used

    | Medication | Typical Starting Dose | Maintenance Dose | Administration |

    |---------------|-----------------------|---------------------------|-------------------|

    | Liraglutide | 0.6 mg daily | 1.2–1.8 mg daily | Subcutaneous inj. |

    | Semaglutide | 0.25 mg weekly | 0.5–1 mg weekly | Subcutaneous inj. |

    | Dulaglutide | 0.75 mg weekly | 1.5 mg weekly | Subcutaneous inj. |

    | Exenatide | 5 mcg twice daily | 10 mcg twice daily | Subcutaneous inj. |

    Initiating Therapy

  • Start with a low dose to minimize gastrointestinal side effects (nausea, vomiting).
  • Titrate gradually every 1-2 weeks based on tolerance and glycemic response.
  • Regular monitoring of blood glucose and cardiovascular status is recommended.

    • Patient Selection

  • Ideal for patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD) or at high cardiovascular risk